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We developed an adenovirus-based CRISPR/Cas9 system for gene editing in vivo. In the liver, we
demonstrated that the system could reach the level of tissue-speciﬁc gene knockout, resulting in
phenotypic changes. Given the wide spectrum of cell types susceptible to adenoviral infection,
and the fact that adenoviral genome rarely integrates into its host cell genome, we believe the
adenovirus-based CRISPR/Cas9 system will ﬁnd applications in a variety of experimental settings.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Developments in DNA-based methodologies have greatly
enhanced our ability to manipulate genetic materials. The CRISPR
(clustered regularly interspaced short palindromic repeat)/Cas9
system is the latest development that allows much simpliﬁed
and efﬁcient gene editing in many settings including cultured
human cells and fertilized rodent oocytes [1–7]. Although
gene-targeted, even conditionally targeted rodents can now be
generated rather efﬁciently through the use of CRISPR/Cas9 [1,8],
the so-generated rodents have still to go through time-consuming
breeding procedures in order to generate homozygous animals for
phenotypic and functional analyses. With our interests in liver
physiology and pathology, we sought to determine if we could
perform CRISPR/Cas9-mediated gene editing in adult mouse liverto obtain liver gene knockouts directly without resorting to
knockout in the germline ﬁrst strategy. Therefore, we adapted
the CRISPR/Cas9 system into adenoviral vectors (Fig. 1A). We
generated two pENTRY vectors, one to express a single sgRNA
and the wildtype Cas9, and another to express double sgRNA and
D10ACas9 for the double nicking strategy [9]. Cas9 has two activity
centers each one of which is responsible for the cutting of one
strand of the double-strand DNA. The double nicking strategy
makes use of a mutant form of Cas9 which harbors a point muta-
tion that eliminates the activity of one of the activity centers such
as the D10A mutant. The mutant Cas9 can only cut one strand now
to generate a nick on a double strand DNAmolecule. With two sgR-
NAs targeting to a site, the mutant Cas9 can still generate a double
strand break at the site, whereas at off-target sites, it could only
make one cut (nick), because it is extremely unlikely that the off-
targets of the two sgRNAs would co-exist. Nicks on DNA are rapidly
and efﬁciently repaired through the nuclear excision repair
pathway in cells, leaving no change or mutation behind.
Once sgRNA sequences are cloned into these two vectors, the
pENTRYs can be cloned into an adenoviral destination vector via
the convenient gateway strategy. The resultant vectors were
Fig. 1. Adenoviral delivery of CRISPR/Cas9. (A) Diagrams of two pENTRY vectors for cloning of sgRNA sequences. (B) Efﬁcient gene editing with adenoviral CRISPR/Cas9.
NIH3T3 cells were infected with adenoCas9 against GFP (control) or Mcc1 (see C for sgRNA sequence) for 4 days and harvested for T7EN I gene editing analysis. In addition,
NIH3T3 cells were ﬁrst infected with lentiviruses (pLKO.1-based) expressing the same sgRNA and then infected with adenoviruses expressing Cas9 or lentiviruses expressing
Cas9. 7 days after the infection, the cells were harvested and subjected to T7EN I assay. (C) Illustration of Mcc1 locus with sgRNA and PAM sequences highlighted. 5 edited
sequences were also shown.
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Fig. 2. Gene editing in adult mouse liver. (A) T7EN I assay. AdenoCas9n viruses with single- and double-sgRNA as well as the buffer in which the viruses were suspended for
injection (control) were injected into 6-week old male C57BL/6 mice via tail vein. 7 days after the injection, 2/3 of the livers from the injected animals were removed for
analyses. (B) Illustration of Cebpa locus with sgRNA and PAM sequences highlighted. 5 edited sequences were also shown. (C) Western blot analysis of CEBPa levels. (D)
Quantitative PCR analysis of the expression of Cebpa downstream genes in the livers (n = 3). Student t tests were run to determine the statistic signiﬁcance. n.s., not
signiﬁcant; ⁄⁄, p < 0.01.
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Fig. 3. Gene editing in the liver is maintained after partial hepatectomy. (A) Pictures of the livers 7 days after 2/3 hepatectomy (14 days after the virus injection). (B) Liver
over body weight ratios. (C) T7EN I assay. (D) Western blot analysis of CEBPa levels. (E) Quantitative PCR analysis of the expression of Cebpa downstream genes in the livers
(n = 3). Student t tests were run to determine the statistic signiﬁcance. n.s., not signiﬁcant; ⁄⁄, p < 0.01. (F) T7EN I assay of the edited Cebpa locus 90 days after the injection of
the adenoCas9n viruses with double-sgRNA. (G) Western blot analysis of CEBPa levels 90 days after the injection of the adenoCas9n viruses with double-sgRNA. The control
was a mouse with adenoCas9 carrying a sgRNA against GFP.
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packaged into adenoviruses in 293A cells. The viral particles were
concentrated and puriﬁed through gradient centrifugation. We
ﬁrst tested the efﬁciency of adenoCas9. In NIH 3T3 ﬁbroblasts,
we observed near identical gene editing efﬁciencies against Mcc1
among 3 different CRISPR/Cas9 delivery systems (Fig. 1B). Adeno-
Cas9 produced expected indels inMcc1 (Fig. 1C). In 20 PCR product
clones sequenced, we could ﬁnd only one wildtype. In other words,
95% of the PCR products were indels. There were two scenarios that
could explain the sequencing result, assuming that the wildtype
and indel alleles were PCR ampliﬁed with an equal efﬁciency and
that the cells were diploid. In the ﬁrst scenario, a 95% indel rate
could result from 95% of the cells being / (‘‘’’ denotes a indel)
and 5% +/+. Thus in 20 cells (for the simplicity of calculation), there
would be 19 that were /, or 38 indel alleles, and 1 wildtype cell
or 2 wildtype alleles, giving rise to a indel rate of 95% (38/40). In
the second scenario, the same indel rate of 95% could result from
90% of the cells being / and 10% +/. Thus in 20 cells, there
would be 18 cells that were /, or 36 indel alleles, and 2 cells
+/, or 2 wildtype alleles and 2 indel alleles. The end result is sill
the same, 38 indel alleles and 2 wildtype alleles, or an indel rate
of 95% (38/40). In reality, the situation is very likely to be some-
where between these two scenarios, but at least 90% (the second
scenario) of the cells were homozygous indels.
Having demonstrated the efﬁciency of AdenoCas9, we wanted
to test it in adult mouse liver which is susceptible to adenovirus
infection. We chose Cebpa as the target. Cebpawas among the tran-
scription factors identiﬁed in our liver proteome project to be sys-
tematically screened for their functions in the liver. It was chosen
because the conditional knockout had been described so that we
could determine if the knockout in adult mouse liver throughCRISPR/Cas9 was feasible. We injected (1  1010 virus particles/
animal) adenoCas9n targeting Cebpa (and viruses carrying a single
sgRNA and Cas9n as well as the buffer in which the viruses were
suspended as controls) into mice via tail vein. It is known that
the vast majority of adenoviruses injected into tail vein ends up
in the liver and other organs and tissues are spared. 7 days after
the injection, we sacriﬁced the animals, isolated the liver, and
extracted genomic DNA, total RNA, and proteins for analyses. A
200 bp region of Cebpa encompassing the predicted Cas9 cutting
site was ampliﬁed from the extracted genomic DNA and subjected
to T7EN I mismatch assay, or cloned and sequenced. Efﬁcient edit-
ing of Cebpa was observed (Fig. 2A). Sequencing of the cloned PCR
products showed typical indels (Fig. 2B). Over 90% of the PCR
clones were in mutant forms. According to the calculation per-
formed above, a 90% indel rate could result from the liver cells
being 90% / and 10% +/+ or 80% / and 20% +/ cells. Either
way, an effective Cebpa knockout had been achieved with this
approach. Indeed, Western blot analysis demonstrated diminished
CEBPa levels in the livers (Fig. 2C). CEBPa is a transcription factor
important for the expression of metabolic genes in the liver
[10–13]. We chose 2 of them, Saas4 and Ascl4, whose expression
depends on Cebpa to determine whether their expression was
affected in the mice treated with adenoCas9n. As shown in
Fig. 2D, their expression indeed decreased greatly, similar to the
result obtained with liver-speciﬁc Cebpa knockouts [10,13]. Taken
together, these results demonstrate that our adenoCas9n achieved
an effective gene knockout in the liver.
To make sure there are no unwanted editing, we analyzed 5 top
off-target sites for each of the two sgRNAs targeting Cebpa
(Fig. S1). 200 bp encompassing the potential off-target sites were
ampliﬁed through limited numbers of PCR cycles over relatively
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Fig. 4. Adenoviral expression of Cas9 diminishes with time. (A) Western blotting
analysis of Flag-tagged Cas9. (B) Q-PCR analysis Cas9 mRNA. (C) Q-PCR analysis of
adenoviral genome present in the liver.
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sampling of the off-target sites and to minimize PCR-introduced
errors. The PCR products were deep sequenced with each being
sequenced close to 2 million times. At all 10 suspected sites, we
could not detect any signs of editing.
The mouse liver is remarkable in that it can regenerate from the
remaining cells after partial hepatectomy. The CRISPR/Cas9-
mediated gene editing is on genomic DNA and should be stable
along with cell divisions. To determine whether the editing of
Cebpa is stable, we performed partial hepatectomy (2/3 of the liver
removed) 7 days after the injection of the viruses. 7 days later
(14 days after virus injection), we harvested the livers which had
already grown back. Interestingly, the livers from double Cebpa
sgRNAs/Cas9-injected mice were much larger than the controls
(Fig. 3A and B). The Cebpa locus were still edited as before
(Fig. 3C), and CEBPa protein levels were much lower as well in
the edited than controls (Fig. 3D). Again, the two downstream
genes of CEBPa were expressed at much lower levels in the edited
than in controls (Fig. 3E). Moreover, the editing remained evident
3 months after the injection of viruses (Fig. 3F and G). These results
demonstrate that Cas9-mediated gene editing is stable in vivo over
long term, and even after the extensive regeneration of the liver
tissue.Next, we analyzed the expression of Cas9 after the injection of
the viruses. As expected, its expression rapidly decayed at both
protein (Fig. 4A) and mRNA (Fig. 4B) levels, most likely due to
the immune responses-mediated clearance of the viral genome.
Indeed, the viral genome content in the infected livers rapidly
decreased with time. By 90 days after the injection, the adenoviral
genome content was about 1% of that at 2 days after the injection,
but the editing persisted (Fig. 3F and G).
The adenoviral strategy described here opens the door for gene
editing in vivo in adult animals, especially in the liver where an
effective gene knockout can be achieved. Adenoviruses have been
widely used in delivering shRNAs into mouse liver for functional
studies [11], but the knockdown effect is transient and is in no
comparison to what we obtained here. Our strategy will allow very
fast genetic interrogation of gene functions, even genetic screening
in the liver, aimed at delineating metabolic and other important
functions performed by this vital organ. Further, since liver dis-
eases such as non-alcohol fat liver disease and hepatitis are major
health threats worldwide, adenoviral CRISPR/Cas9 systems could
be developed into therapeutics against the culprit genes that are
behind the diseases. Our study together with the recent reports
of the use of CRISPR/Cas9 in the liver, from rapid establishments
of animal models [14] to the correction of a disease-causing muta-
tion in mice [15], demonstrate a broad utility of CRISPR/Cas9-med-
iated gene editing in the liver.
2. Materials and methods
2.1. Plasmids and viruses
Constructs used in the work were generated through standard
cloning methods. The human codon optimized Cas9 was reported
previously [3]. Packaging of helper-free adenoviruses was done
according to published protocols and puriﬁcation of infectious viral
particles was achieved through CsCl gradient centrifugation. The
T7EN I gene editing assay was reported previously [3]. All animal
protocols were approved by the Animal Care and Use Committee
of the Beijing Proteome Research Center. Partial hepatectomy
was performed with the established procedure [16].
2.2. DNA/RNA extraction and quantiﬁcation
Genomic DNA was extracted from cells or liver tissues with an
established protocol. In brief, cells or tissues were lysed in 1% SDS/
5 mM EDTA/10 mM Tris–HCl pH 8.0/0.1 M NaCl/200 lg/ml Pro-
teinase K (Roche) and digested overnight at 55 C. The lysates were
then extracted with phenol/chloroform and genomic DNA precipi-
tated with ethanol.
Total RNA was extracted from liver tissues frozen in liquid
nitrogen using Trizol (Invitrogen). 1 lg of total RNA was used for
cDNA synthesis using a reverse transcription kit (Promega).
Quantitative PCR (QPCR) was performed and analyzed with Bio-
Rad CFX Connect Real Time system using SYBR Green Master (Rox)
(Roche). Primers for QPCR are listed below: Gapdh-F, 50AGGTCG
GTGTGAACGGATTTG30, Gapdh-R, 50TGTAGACCATGTAGTTGAGGT
CA30; Saa4-F, 50CCAGGGCCTCCTAAACCGATA30, Saa4-R, 50CTCGGG
TCGGAAGTGATTGG30, Acsl1-F, 50TGCCAGAGCTGATTGACATTC30,
Acsl1-R, 50GGCATACCAGAAGGTGGTGAG30; Cas9-F, 50CCGCTTACCG
GATACCTGTC30, Cas9-R, 50TTGGAGCGAACGACCTACAC30.
To quantify adenoviral genome, genomic DNA (including the
viral genome which exists as episome) was subjected to quantita-
tive PCR analysis with primers against actin (on genomic DNA for
internal control) and adenoviral backbone (pAd). The primer
sequences are: actin-F, 50AACAGTCCGCCTAGAAGCAC30, actin-R,
50CGTTGACATCCGTAAAGACC30; pAd-F: 50AAAGCCGTTGATGTTGT
GGC30, pAd-R, 50TGGGAACAAGACCCGCTTAC30.
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For Western blotting, fresh liver tissues were homogenated and
lysed in RIPA buffer with 2.5 ll/ml protease inhibitor cocktail
(Roche) on ice for 15 min. The protein concentrations were deter-
mined with Bradford method (Bio-Rad). The primary antibodies
for Western blotting included: anti-Cebpa (Boater), anti-FlAG
(Sigma), and anti-GAPDH (Santa Cruz).
2.4. Off-target analysis
Potential off-target sequences of each of the two Cebpa sgRNAs
were identiﬁed using the CRISPR design tool (http://tools.genome-
engineering.org) and we selected 5 based on the similarity in the
seed sequence region (12 nt 50 to PAM) as well as the ranking
scores. For deep sequencing of the off-target sites, each locus
(200 bp) was ampliﬁed in 5 separate 50 ll reactions with 5 lg
genomic DNA with 20 cycles using KOD FX DNA Polymerase (TOY-
OBO). The 5 ampliﬁcation reactions were mixed and gel puriﬁed.
The puriﬁed amplicons were subjected to a second PCR ampliﬁca-
tion to attach Illumina adaptors and barcodes and sequenced on a
MiSeq (Illumina) with a single-end 150 bp run at Beijing Genome
Institute (BGI).
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